Phase 2 Oncology Deal Benchmarks
Market Analysis
Phase 2 oncology licensing deals carry a median total deal value of $1.6B, with upfront payments ranging from $144M to $365M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 16% to upfront and 84% to milestones.
The oncology landscape at the phase 2 stage is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. Development milestones average $345M, regulatory milestones contribute $552M, and commercial milestones reach $483M. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors.
Royalty rates for phase 2 oncology deals range from 11.8% to 19.3% at the base tier, with high-tier escalation to 23.3%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average upfront payment for phase 2 oncology deals?
How are phase 2 oncology deal milestones structured?
What royalty rates are typical for phase 2 oncology licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.